Literature DB >> 22011619

Nonerythropoietic properties of erythropoietin: implication for tissue protection.

Dhanesh B Rathod1, Abdulla K Salahudeen.   

Abstract

Erythropoietin (EPO) is used at present in clinical practice to stimulate red cell production. However, a number of reports have emerged suggesting the presence of nonerythropoietic properties for EPO. Chief among them is its ability to confer protection against acute tissue injury. In this report, we briefly review the role of EPO in tissue protection and provide examples of tissue protection using cisplatin-induced kidney injury model. Also provided is a brief description of potential pathways through which EPO may be mediating this effect.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22011619     DOI： 10.2310/JIM.0b013e31822cf86e

Source DB:  PubMed          Journal:  J Investig Med        ISSN： 1081-5589            Impact factor:   2.895


  9 in total

1.  Erythropoietin Stimulates Tumor Growth via EphB4.

Authors:  Sunila Pradeep; Jie Huang; Edna M Mora; Alpa M Nick; Min Soon Cho; Sherry Y Wu; Kyunghee Noh; Chad V Pecot; Rajesha Rupaimoole; Martin A Stein; Stephan Brock; Yunfei Wen; Chiyi Xiong; Kshipra Gharpure; Jean M Hansen; Archana S Nagaraja; Rebecca A Previs; Pablo Vivas-Mejia; Hee Dong Han; Wei Hu; Lingegowda S Mangala; Behrouz Zand; Loren J Stagg; John E Ladbury; Bulent Ozpolat; S Neslihan Alpay; Masato Nishimura; Rebecca L Stone; Koji Matsuo; Guillermo N Armaiz-Peña; Heather J Dalton; Christopher Danes; Blake Goodman; Cristian Rodriguez-Aguayo; Carola Kruger; Armin Schneider; Shyon Haghpeykar; Padmavathi Jaladurgam; Mien-Chie Hung; Robert L Coleman; Jinsong Liu; Chun Li; Diana Urbauer; Gabriel Lopez-Berestein; David B Jackson; Anil K Sood
Journal:  Cancer Cell       Date:  2015-10-17       Impact factor: 31.743

2.  Endogenous erythropoietin varies significantly with inflammation-related proteins in extremely premature newborns.

Authors:  J Wells Logan; Elizabeth N Allred; Raina N Fichorova; Stephen Engelke; Olaf Dammann; Alan Leviton
Journal:  Cytokine       Date:  2014-06-02       Impact factor: 3.861

Review 3.  Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.

Authors:  Jules A A C Heuberger; Joost M Cohen Tervaert; Femke M L Schepers; Adriaan D B Vliegenthart; Joris I Rotmans; Johannes M A Daniels; Jacobus Burggraaf; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

4.  Effects of erythropoietin on osteoblast proliferation and function.

Authors:  Lvhua Guo; Tao Luo; Ying Fang; Lan Yang; Liping Wang; Jingwen Liu; Bin Shi
Journal:  Clin Exp Med       Date:  2012-11-08       Impact factor: 3.984

5.  Influence of erythropoietin on microvesicles derived from mesenchymal stem cells protecting renal function of chronic kidney disease.

Authors:  Yan Wang; Xingyan Lu; Juan He; Weihong Zhao
Journal:  Stem Cell Res Ther       Date:  2015-05-22       Impact factor: 6.832

6.  Acute hemodynamic effects of erythropoietin do not mediate its cardioprotective properties.

Authors:  Ismayil Ahmet; Edward G Lakatta; Mark I Talan
Journal:  Biol Open       Date:  2012-08-22       Impact factor: 2.422

7.  Improving outcomes of acute kidney injury using mouse renal progenitor cells alone or in combination with erythropoietin or suramin.

Authors:  Xiao Han; Li Zhao; Guodong Lu; Junke Ge; Yalin Zhao; Shulu Zu; Mingzhen Yuan; Yuqiang Liu; Feng Kong; Zhiying Xiao; Shengtian Zhao
Journal:  Stem Cell Res Ther       Date:  2013-06-18       Impact factor: 6.832

8.  Cardioprotective effect of erythropoietin on sepsis-induced myocardial injury in rats.

Authors:  Yan-Jun Qin; Xin-Liang Zhang; Yue-Qing Yu; Xiao-Hua Bian; Shi-Min Dong
Journal:  World J Emerg Med       Date:  2013

9.  The influence of erythropoietin on apoptosis and fibrosis in the early phase of chronic pancreatitis in rats.

Authors:  Weronika Kazmierak; Agnieszka Korolczuk; Jacek Kurzepa; Grażyna Czechowska; Anna Boguszewska-Czubara; Agnieszka Madro
Journal:  Arch Med Sci       Date:  2020-10-12       Impact factor: 3.318
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.